logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Anavex Announced US Patent Office Granted a Patent No. 11,813.242 Entitled A273 a Therapeutic for Insomnia, Anxiety and Agitation

Anavex Life Sciences Granted US Patent Anavex Life Sciences ( AVXL ) – a development-stage biopharmaceutical company announced that the United States Patent and Trademark Office ( USPTO ) granted U.S. Patent No. 11,813,242 entitled “A273 as a therapeutic for insomnia, anxiety, and agitation.  This patent expands Anavex’s existing patent coverage of ANAVEX®273 (blarcamesine), including U.S. Patent No. 11,337,953 to cover Anavex’s leading drug candidate, ANAVEX®2-73, and NANVEX®14141...

Read More

November 22, 2023

0

Immunovant Inc: Positive IMVT-1402 Results that Would Confirm Best-in-Class Potential in Treating Autoimmune Diseases

Immunovant Inc in the NEWS Immunovant, Inc. ( IMVT ) announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of its product IMVT-1402 in healthy adults. The Phase 1 clinical trial is a randomized, double-blind,...

Read More

November 28, 2023

0

Carlisle Companies Inc and Arcturus Therapeutics Granted Approval in Japan of a Novel Self-Amplifying mRNA Vaccine for COVID-19  

Carlisle Companies Inc and Arcturus Therapeutics in the NEWS Today, November 28, 2023, Global biotechnology leaders Carlisle Companies Inc ( CSL )  and Arcturus Therapeutics ( ARCT ) announced that Japan's Ministry of Health, Labor and Welfare ( MHLW ) granted...

Read More

November 28, 2023

0

AbbVie Inc to Acquire ImmunoGen

AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. ( ABBV ) and ImmunoGen ( IMGN ) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug...

Read More

November 30, 2023

0

EyePoint Pharmaceuticals: Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD

EyePoint Pharmaceuticals Treating Wet Age-Related Macular Degeneration In today's press release , EyePoint Pharmaceuticals ( EYPT ) announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular...

Read More

December 4, 2023

0

Roche Announces Positive Phase III Results for Inavolisib Combination in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

Roche in the NEWS From Basel, today, December 5, 2023 - Roche ( RHHBY ) announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib ( Ibrance® ) and fulvestrant as a...

Read More

December 5, 2023

0

Vertex Stock Soars Pre-Market Announcing Positive Results from Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Vertex Pharmaceuticals in the NEWS Today, December 13, 2023, Vertex  Pharmaceuticals ( VRTX ) announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy ( DPN ). Treatment...

Read More

December 13, 2023

0

Editas Medicine and Vertex Pharmaceuticals: Non-Exclusive License Agreement in Cas9 Gene Editing Technology  

Editas Medicine and Vertex Pharmaceuticals in the NEWA Today December 13, 2023, Editas Medicine ( EDIT ) announced that it entered into an agreement with Vertex Pharmaceuticals ( VRTX ) . The Terms of the Agreement: Vertex will obtain a...

Read More

December 13, 2023

0

Merck & Invivyd in Today's December 18, 2023 News

Merck & Invivyd in the NEWS Our post today comprises a premarket drug rejection. An important new approval for Merck's ( MRK ) Keytruda product, and exciting promising trial results for the firm Invivyd, Inc. ( IVVD ) viral protection....

Read More

December 18, 2023

0

CymaBay Therapeutics: New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement

CymaBay Therapeutics in the NEWS CymaBay Therapeutics ( CBAY ) today announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 ( IL-31 ) levels and its correlation with pruritus improvement in people with primary biliary cholangitis...

Read More

January 3, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 167
  • 168
  • 169
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy